Duloxetine for the Prevention of Oxaliplatin Induced Peripheral Neuropathy: A Randomized, Placebo-Controlled, Double-blind Clinical Trial
ConclusionAlthough a definite conclusion might be difficult to draw but administering duloxetine for 14 days in each chemotherapy cycle could not decrease the incidence of acute OIPN based on CTCAE grading system.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Cymbalta | Eloxatin | Gastroenterology | Neurology | Peripheral Neuropathy | Rectal Cancers | Study